Literature DB >> 26422944

[Levobupivacaine for Ultrasound-guided Interscalene Block: Block with 6 ml Leads to Less Occurrence of Respiratory Depression and Hemidiaphragmatic Paralysis].

Taketo Nakamura, Shinnosuke Miyamoto, Keikoh Aishin, Megumi Hashimoto.   

Abstract

BACKGROUND: Interscalene brachial plexus block (ISBPB) complications depend usually on the dose administered.
METHODS: The object of this study was to determine whether ultrasound-guided ISBPB with 6 ml of 0.5% levobupivacaine would reduce occurrence of respiratory depression and hemidiaphragmatic paralysis.
RESULTS: Patients undergoing arthroscopic shoulder surgery under nerve block with general anesthesia (n = 20) were recruited. There were no differences between pre and post operative respiratory function (forced expiratory volume 1.0 (sec) % and vital capacity). Hemidiaphragmatic paralysis on postoperative ultrasonography was found in two patients.
CONCLUSIONS: The use of low-volume ultrasound-guided ISBPB is associated with less respiratory depression and hemidiaphragmatic paralysis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26422944

Source DB:  PubMed          Journal:  Masui        ISSN: 0021-4892


  2 in total

1.  Diaphragmatic paralysis in obese patients in arthroscopic shoulder surgery: consequences and causes.

Authors:  Philippe Marty; Fabrice Ferré; Bertrand Basset; Constance Marquis; Benoit Bataille; Martine Chaubard; Mehdi Merouani; Olivier Rontes; Alain Delbos
Journal:  J Anesth       Date:  2018-03-06       Impact factor: 2.078

2.  Diaphragmatic paralysis, respiratory function, and postoperative pain after interscalene brachial plexus block with a reduced dose of 10 ml levobupivacaine 0.25% versus a 20 ml dose in patients undergoing arthroscopic shoulder surgery: study protocol for the randomized controlled double-blind REDOLEV study.

Authors:  P Oliver-Fornies; J P Ortega Lahuerta; R Gomez Gomez; I Gonzalo Pellicer; L Oliden Gutierrez; J Viñuales Cabeza; L Gallego Ligorit; C E Orellana Melgar
Journal:  Trials       Date:  2021-04-19       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.